维普期刊资源整合服务平台（V6.5）

23篇 您的检索式：作者名="DYTFELD D"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Plasma homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients显示文摘	Bogdanski P Pupek-Musialik D Dytfeld J	2008	Biomed Pharmacother2008，62，6：	1
2	Expression of chemokine receptor CCR5 in patients with type 2 diabetes显示文摘	Dytfeld J Bogdanski P Pupek-Musialik D	2006	Pol Merkur Lekarski2006，20，116：	1
3	Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus 显示文摘	BOGDANSKI P PUPEK-MUSIALIK D DYTFELD J	2007	Int J Clin Pharmacol Ther2007，45，10：	1
4	Expression of chemokine receptor CCR5 in patients with type 2 diabetes 显示文摘	DYTFELD J BOGDASKI P PUPEK-MUSIALIK D	2006	Pol Merkur Lekarski2006，20，116：	1
5	Influence of in-sulin therapy on expression of chemokine receptor CCR5 and se-lected inflammatory markers in patients with type 2 diabetes melli-tus显示文摘	Bogdansk P Pupek-Musialik D Dytfeld J	2007	Int J Clin Pharmacol Ther2007，45，10：	1
6	Plasma homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients显示文摘	Bogdanski P Pupek-Musialik D Dytfeld J	2008	Biomed Pharmacother2008，62，6：	1
7	Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortczomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by afree light chain - and M - protein - based model : Extended follow - up of a phase II trial显示文摘	Dytfeld D Griffith KA Friedman J	2011	Leuk Lymphoma2011，52，7：	1
8	Plasma homocysteine is a deter minant of tissue necrosis factor-alpha in hypertensive patients 显示文摘	Bogdanski P Pupek-Musialik D Dytfeld J	2008	Biomed Pharmacother2008，62，：	1
9	Activity of borte- zomib in adult de novo and relapsed acute myeloid leukemia显示文摘	GIL L STYCZYNSKI J DYTFELD D	2007	Anticancer Res2007，27，6：	1
10	Superior overall survival of patients with myeloma achieving very' good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a fi'ee light chain- and M-protein-based model: extended follow-up of a phase II trial 显示文摘	Dytfeld D Griffith KA Friedman J	2011	Leuk Lymphoma2011，52，7：	1
11	A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma显示文摘	Jakubowiak AJ Dytfeld D Griffith KA		0，，：	1
12	Plasma homocysteine is a determinant of tissue necrosis factor alpha in hypertensive patients 显示文摘	Bogdanski P Pupek-Musialik D Dytfeld J	2008	Biomed Pharmacother2008，62，6：	1
13	Bortezomib in combination with thalidomide and dexamethasone-a successful treatment regimen in refractory extramedullary multiple myeloma显示文摘	DYTFELD D MATUSZAK M LEWANDOWSKI K	2008	Ann Hematol2008，87，：	1
14	Bortezomib in combination with thalidomide and dexamethasone-a successful treatment regimen in refractory extramedullary multiple myeloma显示文摘	Dytfeld D Matuszak M Lewandowski K		0，，：	1
15	Plasma homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients显示文摘	Bogdanski P Pupek-Musialik D Dytfeld J	2008	Biomed Pharmacother2008，62，6：	1
16	A phase 1/2 study of caffilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma显示文摘	Jakubowiak AJ Dytfeld D Griffith KA	2012	Blood2012，120，：	1
17	Bortezomibin combination with thalidomide and dexamethasone--isuccessful treatment regimen in refractory extram edullarymultiple myeloma 显示文摘	Dytfeld D Matuszak M Lewandowski K	2008	Ann Hematol2008，87，3：	1
18	A phase 1/2study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma显示文摘	Jakubowiak AJ Dytfeld D Griffith KA	2012	Blood2012，120，9：	1
19	Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lympho- ma: a single-center experience显示文摘	Czyz A Lojko-Dankowska A Dytfeld D	2013	Med Oncol2013，30，3：	1
20	Plasma homocysteine is a determinant of tis- sue-necrosis factor-alpha in hypertensive patients显示文摘	BOGDANSKI P PUPEK-MUSIALIK D DYTFELD J	2008	Biomed Pharmacother2008，62，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示